"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Hold on to your huaraches: as ...

Lilly is the second drugmaker this week to go to court over the issue, a sign that the pharmaceutical industry is so fed up with the drug discounts that it is trying to overhaul them.

Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

Visit the newsletter archive for our weekly messages to the Pulitzer Center community. The Pulitzer Center is pleased to announce the winner of the first Climate and Labor Grant... As the U.S.

Around the world, Pulitzer Center grantees are reporting on misinformation related to science, climate change, elections, health issues, and fossil fuels. We believe the best way to counter this ...